Leukemia, Chronic Myelogenous

BASICS

DESCRIPTION

Chronic myelogenous leukemia (CML) is a myeloproliferative neoplasm characterized by clonal proliferation of myeloid precursors in the bone marrow with continuing differentiation into mature granulocytes.
The hallmark of CML is Philadelphia chromosome (translocation t[9;22]).
Natural history of the disease evolves in three clinical phases: a chronic phase, an accelerated phase, and a blast phase or crisis (can transform to acute myeloid leukemia [80%] or acute lymphoblastic leukemia [20%]).

EPIDEMIOLOGY

Incidence

Per year, 1.9 cases/100,000 persons
Median age at diagnosis: 65 years
Predominant sex: male > female (1.7:1)

Prevalence

Accounts for 15–20% of adult leukemias

ETIOLOGY AND PATHOPHYSIOLOGY

Philadelphia chromosome is a balanced translocation between BCR (on chromosome 22) and ABL (on chromosome 9) genes t(9;22)(q34;q11). This fusion gene, BCR-ABL, codes for an abnormal, constitutively active tyrosine kinase that affects numerous signal transduction pathways, resulting in uncontrolled cell proliferation and reduced apoptosis.

Genetics

Acquired genomic changes

RISK FACTORS

Ionizing radiation exposure (uncommon)

There's more to see -- the rest of this topic is available only to subscribers.

All content is protected by copyright and may not be used for AI model training or other unauthorized purposes.